← Back to All US Stocks

HYEX Stock Analysis 2026 - HEALTHY EXTRACTS INC. AI Rating

HYEX OTC Medicinal Chemicals & Botanical Products NV CIK: 0001630176
Recently Updated • Analysis: Apr 11, 2026 • SEC Data: 2025-12-31
STRONG SELL
85% Conf
Pending
Analysis scheduled

📊 HYEX Key Takeaways

Revenue: $4.5M
Net Margin: 446.0%
Free Cash Flow: $165.5K
Current Ratio: 0.79x
Debt/Equity: 0.03x
EPS: $0.00
AI Rating: STRONG SELL with 85% confidence

Is HYEX a Good Investment? Thesis Analysis

Claude

Despite exceptional 2245% revenue growth and healthy 53.7% gross margins, the company's core operations are severely unprofitable at -73.7% operating margin. The 20.1M net income with zero YoY growth appears driven by non-operating items rather than sustainable operations. Critical liquidity constraints (0.79x current ratio, only 146.9K cash) combined with negative operating cash breakeven create acute financial distress.

Why Buy HYEX? Key Strengths

Claude
  • + Exceptional YoY revenue growth of 2245.7% demonstrates strong market demand and commercial traction
  • + Healthy gross margin of 53.7% indicates product-market fit and pricing power
  • + Low debt-to-equity ratio of 0.03x minimizes financial leverage and default risk

HYEX Investment Risks to Consider

Claude
  • ! Operating margin of -73.7% reveals core business is fundamentally unprofitable despite revenue growth
  • ! Critical liquidity crisis with current ratio 0.79x and minimal 146.9K cash reserves creates solvency risk
  • ! Net income of 20.1M with 0.0% YoY growth indicates reliance on non-operating items, not operational profitability
  • ! Interest coverage ratio of -41.6x shows inability to service debt from operational earnings
  • ! Zero insider buying activity in 90 days suggests management lacks confidence in fundamentals

Key Metrics to Watch

Claude
  • * Operating margin trajectory - must turn positive to validate business model sustainability
  • * Cash balance and burn rate - immediate solvency threat given liquidity ratios
  • * Operating cash flow consistency - validate if 165.5K FCF is repeatable or one-time

HYEX Financial Metrics

Revenue
$4.5M
Net Income
$20.1M
EPS (Diluted)
$0.00
Free Cash Flow
$165.5K
Total Assets
$27.8M
Cash Position
$146.9K

💡 AI Analyst Insight

The relatively thin 3.7% FCF margin may limit capital allocation flexibility. The current ratio below 1.0x warrants monitoring of short-term liquidity.

HYEX Profitability Ratios

Gross Margin 53.7%
Operating Margin -73.7%
Net Margin 446.0%
ROE 83.7%
ROA 72.3%
FCF Margin 3.7%

HYEX vs Default Sector

How HEALTHY EXTRACTS INC. compares to Default sector averages

Net Margin
HYEX 446.0%
vs
Sector Avg 12.0%
HYEX Sector
ROE
HYEX 83.7%
vs
Sector Avg 15.0%
HYEX Sector
Current Ratio
HYEX 0.8x
vs
Sector Avg 1.8x
HYEX Sector
Debt/Equity
HYEX 0.0x
vs
Sector Avg 0.7x
HYEX Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is HYEX Overvalued or Undervalued?

Based on fundamental analysis, HEALTHY EXTRACTS INC. appears fundamentally strong relative to the Default sector in 2026.

Return on Equity
83.7%
Sector avg: 15%
Net Profit Margin
446.0%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.03x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

HYEX Balance Sheet & Liquidity

Current Ratio
0.79x
Quick Ratio
0.29x
Debt/Equity
0.03x
Debt/Assets
13.6%
Interest Coverage
-41.57x
Long-term Debt
$641.9K

HYEX 5-Year Financial Trend & Growth Analysis

HYEX 5-year financial data: Year 2021: Revenue $1.7M, Net Income -$2.6M, EPS N/A. Year 2022: Revenue $2.3M, Net Income -$2.0M, EPS N/A. Year 2023: Revenue $2.5M, Net Income -$983.1K, EPS N/A. Year 2024: Revenue $3.1M, Net Income -$2.5M, EPS N/A. Year 2025: Revenue $4.5M, Net Income -$840.7K, EPS N/A.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: HEALTHY EXTRACTS INC.'s revenue has grown significantly by 169% over the 5-year period, indicating strong business expansion.

HYEX Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
3.7%
Free cash flow / Revenue

HYEX Quarterly Performance

Quarterly financial performance data for HEALTHY EXTRACTS INC. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $744.9K $354.5K N/A
Q2 2025 $908.4K $67.1K N/A
Q1 2025 $688.8K -$398.9K N/A
Q3 2024 $613.5K -$247.9K N/A
Q2 2024 $588.5K $113.5K N/A
Q1 2024 $614.9K -$579.2K N/A
Q3 2023 $499.7K -$170.2K N/A
Q2 2023 $469.8K -$856.3K N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

HYEX Capital Allocation

Operating Cash Flow
$165.5K
Cash generated from operations
Dividends
None
No dividend program

HYEX SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for HEALTHY EXTRACTS INC. (CIK: 0001630176)

📋 Recent SEC Filings

Date Form Document Action
Apr 9, 2026 10-K hyex-20251231_10k.htm View →
Nov 14, 2025 10-Q hyex-20250930_10q.htm View →
Oct 2, 2025 8-K hyex-20250926_8k.htm View →
Sep 23, 2025 8-K hyex-20250916_8k.htm View →
Aug 22, 2025 4 xslF345X05/form4.xml View →

Frequently Asked Questions about HYEX

What is the AI rating for HYEX?

HEALTHY EXTRACTS INC. (HYEX) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.

What are HYEX's key strengths?

Claude: Exceptional YoY revenue growth of 2245.7% demonstrates strong market demand and commercial traction. Healthy gross margin of 53.7% indicates product-market fit and pricing power.

What are the risks of investing in HYEX?

Claude: Operating margin of -73.7% reveals core business is fundamentally unprofitable despite revenue growth. Critical liquidity crisis with current ratio 0.79x and minimal 146.9K cash reserves creates solvency risk.

What is HYEX's revenue and growth?

HEALTHY EXTRACTS INC. reported revenue of $4.5M.

Does HYEX pay dividends?

HEALTHY EXTRACTS INC. does not currently pay dividends.

Where can I find HYEX SEC filings?

Official SEC filings for HEALTHY EXTRACTS INC. (CIK: 0001630176) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is HYEX's EPS?

HEALTHY EXTRACTS INC. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is HYEX a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, HEALTHY EXTRACTS INC. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is HYEX stock overvalued or undervalued?

Valuation metrics for HYEX: ROE of 83.7% (sector avg: 15%), net margin of 446.0% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.

Should I buy HYEX stock in 2026?

Our dual AI analysis gives HEALTHY EXTRACTS INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.

What is HYEX's free cash flow?

HEALTHY EXTRACTS INC.'s operating cash flow is $165.5K, with capital expenditures of $0.0. FCF margin is 3.7%.

How does HYEX compare to other Default stocks?

Vs Default sector averages: Net margin 446.0% (avg: 12%), ROE 83.7% (avg: 15%), current ratio 0.79 (avg: 1.8).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 11, 2026 | Data as of: 2025-12-31 | Powered by Claude AI